BioAccelerate

BioAccelerate is a life science venture management company and company builder that focuses on identifying, developing, and commercializing early-stage biotechnology assets. The company operates by acquiring or licensing promising intellectual property and forming dedicated subsidiaries to advance these programs through clinical development. BioAccelerate is most notable for its role in founding and developing BioVex, which produced the first FDA-approved oncolytic virus therapy, Imlygic (T-VEC), later acquired by Amgen. The firm's portfolio has historically spanned various modalities, including oncolytic viruses, small molecules, and cell therapies, primarily targeting oncology indications.